Ultrasound-enhanced monoclonal antibody production

  1. Get@NRC: Ultrasound-enhanced monoclonal antibody production (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1016/j.ultrasmedbio.2012.06.008
AuthorSearch for: ; Search for: ; Search for: ; Search for: ; Search for:
Journal titleUltrasound in Medicine & Biology
Pages19491957; # of pages: 9
SubjectUltrasound-enhanced drug production; Low-intensity pulsed ultrasound; Value-added biotechnology; Monoclonal antibody production; Hybridoma
AbstractWith the rapidly growing demand for monoclonal antibody (mAb)–based products, new technologies are urgently needed to increase mAb production while reducing manufacturing costs. To solve this problem, we report our research findings of using low-intensity pulsed ultrasound (LIPUS) to enhance mAb production. LIPUS with frequency of 1.5 MHz and pulse repetition frequency of 1 kHz, as well as duty cycle of 20%, was used to stimulate hybridoma cells to enhance the production of mAb, anti-CD4 (hybridoma GK1.5). The enzyme-linked immunosorbent assay results show a 60.42 ± 7.63% increase of mAb expression in hybridoma cells. The evidence of structural changes of the cellular outer membrane in both transmission electron microscopy and scanning electron microscopy images and the more than 20% lactate dehydrogenase release indicates that the increased mAb production is related to the increased cell permeability induced by LIPUS. This value-added ultrasound technology provides a potential cost-effective solution for pharmaceutical companies to manufacture mAb-based drugs. The technology, in turn, can reduce the drug manufacturing costs and decrease health care spending.
Publication date
AffiliationSecurity and Disruptive Technologies; National Research Council Canada
Peer reviewedYes
NPARC number21268753
Export citationExport as RIS
Report a correctionReport a correction
Record identifier4c825837-0d01-4be2-9888-4e25d90f5559
Record created2013-11-12
Record modified2016-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)